Abivax (ABVX) Payables (2022 - 2026)

Abivax (ABVX) has reported Payables for 5 consecutive years, with $34.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 41.89% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 41.89% YoY), while the FY2025 annual figure was $43.7 million, down 6.66% from the prior year.
• Payables came in at $34.6 million for Q1 2026 at Abivax, down from $43.7 million in the prior quarter.
• The five-year high for Payables was $65.1 million in Q2 2025, with the low at $15.8 million in Q4 2022.
• Average Payables over 5 years is $42.8 million, with a median of $43.7 million recorded in 2025.
• Across the five-year window, Payables surged 221.8% in 2023 and sank 41.89% in 2026, its largest moves.
• Year by year, Payables stood at $15.8 million in 2022, then soared by 221.8% to $50.8 million in 2023, then declined by 7.83% to $46.8 million in 2024, then retreated by 6.66% to $43.7 million in 2025, then decreased by 20.95% to $34.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $34.6 million, $43.7 million, and $35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.